Recently, the press conference for the 2022-2023 listing reserve "Golden Seed" enterprises in Hubei Province was held in Wuhan. Since 2016, in order to accelerate the development of listed companies, Hubei Province has launched the "Golden Seed" plan, with the first batch of 50 enterprises selected. Later, documents such as the "Opinions of the People's Government of Hubei Province on Further Promoting Enterprise Listing Work" and the "Implementation Plan of the Green Channel System for Enterprise Listing Work in Hubei Province" were successively released, providing key support in policy support, listing services, and other aspects to the selected "Golden Seed" enterprises. Over the past six years of cultivation, "Golden Seed" enterprises have become the most valuable reserve force for listing in Hubei Province, and also the first tier of enterprises rushing to go public.

Hubei Mengyang Pharmaceutical Co., Ltd. (hereinafter referred to as "Mengyang Pharmaceutical") has been selected as a reserve "Golden Seed" enterprise for listing in Hubei Province from 2022 to 2023, which is a high recognition of the company's innovation ability, technological level, and market competitiveness. Mengyang Pharmaceutical is a drug research and development and production enterprise driven by research and development, focusing on solving cancer treatment related diseases. Since its establishment, it has been committed to exploring the treasure of traditional Chinese medicine, developing classic formulas of famous traditional Chinese medicine and effective ingredients from natural drugs into drugs that meet clinical needs. The research and development pipeline covers raising white blood cells, protecting the liver, protecting the heart, and raising platelets Cancer related fatigue and other tumor treatment related diseases.

Mengyang Pharmaceutical has been selected as a reserve "Golden Seed" enterprise for listing in Hubei Province, which not only means that its comprehensive competitiveness and development potential have received attention from the government and various sectors of society, but also represents an important step for the company to go public and enter the "fast lane" of development. In the future, Mengyang Pharmaceutical will continue to uphold the mission of "improving the quality of life of cancer patients", practice the values of "patient-centered, guided by unmet clinical needs, adhering to integrity and innovation, and continuous struggle", walk the path of high-quality development, deeply cultivate and work in the field of tumor treatment related diseases, and write a magnificent chapter.